181 results on '"Dunayevich, Eduardo"'
Search Results
2. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial
3. Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia.
4. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia
5. Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms
6. Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 2—External Validity and Correlates
7. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
8. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients
9. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia
10. Sustained Treatment Response with Long-Term Valbenazine in Patients with Tardive Dyskinesia (P11-11.012)
11. Sustained Treatment Response With Long-Term Valbenazine in Patients With Tardive Dyskinesia
12. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
13. Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE dataset
14. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
15. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects
16. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
17. Long-term Safety and Efficacy of Add-on Cannabidiol in Patients with Lennox-Gastaut Syndrome: Results of a Long- Term Open-Label Extension Trial:CBD long-term safety and efficacy in Lennox-Gastaut syndrome
18. Add‐on cannabidiol in patients with Dravet syndrome: Results of a long‐term open‐label extension trial
19. Bayesian adaptive non-inferiority with safety assessment: Retrospective case study to highlight potential benefits and limitations of the approach
20. Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial
21. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
22. Characteristics of two alternative schizophrenia remission definitions: Relationship to clinical and quality of life outcomes
23. Prevalence and description of psychotic features in bipolar mania
24. Atypical Antipsychotics in the Treatment of Bipolar Disorder: Pharmacological and Clinical Effects
25. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
26. Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
27. Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome (LGS): 3-Year Results of an Open-Label Extension (OLE) Trial (GWPCARE5) (668)
28. Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome (DS): 3-Year Interim Results of an Open-Label Extension (OLE) Trial (GWPCARE5) (439)
29. Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
30. NONRESPONSE, PARTIAL RESPONSE, AND FAILURE TO ACHIEVE REMISSION: HUMANISTIC AND COST BURDEN IN MAJOR DEPRESSIVE DISORDER
31. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia
32. A pilot study of rapid lithium administration in the treatment of acute mania
33. Quetiapine for Treatment-Resistant Mania
34. Olanzapine-Induced Tardive Dystonia
35. Risperidone and Clozapine for Treatment-Resistant Schizophrenia
36. (CBD) Significantly Reduces Convulsive Seizure Frequency in Dravet Syndrome: Results of a Dose-Ranging, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial
37. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
38. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
39. (CBD) Significantly Reduces Convulsive Seizure Frequency in Dravet Syndrome: Results of a Dose-Ranging, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial.
40. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia
41. Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder
42. WEIGHT LOSS, BLOOD PRESSURE, PULSE AND CIRCADIAN PATTERNS WITH NALTREXONE SUSTAINED-RELEASE/BUPROPION SUSTAINED-RELEASE COMBINATION THERAPY FOR OBESITY
43. Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
44. Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation
45. Rational Design of a Combination Medication for the Treatment of Obesity
46. Erratum: Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder
47. Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder
48. Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder
49. All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics
50. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.